Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 6/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12730491 | 0.86 | MET (0.58) | PIM1METNQO2PDE3BPDE3A | |
| SCHEMBL13575023 | 0.86 | MET (0.44) | PIM1NPSR1MAPTMETNQO2 | |
| SCHEMBL1134053 | 0.84 | MET (0.44) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1133778 | 0.83 | MET (0.43) | PIM1METNQO2PDE3BPDE3A | |
| SCHEMBL1133887 | 0.83 | CYP1A2 (0.43) | PIM1METNQO2PDE3BPDE3A | |
| SCHEMBL1133888 | 0.83 | CYP1A2 (0.43) | PIM1METNQO2PDE3BPDE3A | |
| SCHEMBL12224240 | 0.78 | DYRK1A (0.46) | PIM1NPSR1MAPTMETNQO2 | |
| SCHEMBL12730492 | 0.78 | MET (0.44) | METPDE3BPDE3AKDM4E | |
| SCHEMBL12730513 | 0.77 | MET (0.41) | PIM1METNQO2PDE3BPDE3A | |
| SCHEMBL13575027 | 0.75 | LRRK2 (0.42) | NPSR1MAPTMETNQO2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285811-B1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-12-05 | — | — | EP | claimed |
| JP-2011524385-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-2285811-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-Ý1,2,4¨TRIAZOLOÝ4,3-B¨PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-02-23 | — | — | EP | claimed |
| WO-2009152920-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | claimed |
| EP-2285811-B1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| EP-2285811-B1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2009152920-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | RET, ERBB2, MET | PIM1 73/4885NPSR1 2230/4885MAPT 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.